SCHEMBL837746

SCHEMBL837746

CCOC(=O)c1cnc2ccc(C#N)cc2c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 5/20 0.49
NPC1 O15118 2/20 0.46
TDP1 Q9NUW8 1/20 0.46
RAB9A P51151 1/20 0.46
PDGFRB P09619 2/20 0.46
PDGFRA P16234 1/20 0.46
PDE5A O76074 1/20 0.44
GRM5 P41594 1/20 0.43
KDM4E B2RXH2 3/20 0.43
ALDH1A1 P00352 3/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
HSD17B10 Q99714 2/20 0.43
LMNA P02545 1/20 0.43
MAPT P10636 1/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43
CHRNB2 P17787 1/20 0.42
CHRNA7 P36544 1/20 0.42
CHRNA4 P43681 1/20 0.42
TSHR P16473 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26680685 0.81 MAOB (0.56) MAOBNPC1RAB9APDGFRBPDGFRA
SCHEMBL29793278 0.81 MAOB (0.56) MAOBNPC1RAB9APDGFRBPDGFRA
SCHEMBL6937621 0.81 CA12 (0.51) TDP1GRM5KDM4EALDH1A1SMN1; SMN2
SCHEMBL26681960 0.80 MAOB (0.61) MAOBNPC1TDP1RAB9APDGFRB
SCHEMBL846386 0.80 TSHR (0.61) MAOBNPC1TDP1RAB9APDGFRB
SCHEMBL26798599 0.80 LMNA (0.54) MAOBNPC1RAB9APDGFRBPDGFRA
SCHEMBL2205670 0.80 ALDH1A1 (0.52) MAOBNPC1RAB9APDGFRBPDGFRA
SCHEMBL4398696 0.80 MAOB (0.56) MAOBNPC1RAB9APDGFRBPDGFRA
SCHEMBL838612 0.79 MGAM (0.57)
SCHEMBL545163 0.79 MAOB (0.65) MAOBNPC1TDP1RAB9APDGFRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8883786-B2 Glucocorticoid receptor antagonists HOFFMANN-LA ROCHE INC. (US) 2014-11-11 US disclosed
US-20130045972-A1 GLUCOCORTICOID RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2013-02-21 US disclosed
US-8143280-B2 Glucocorticoid receptor antagonists HOFFMANN-LA ROCHE INC. (US) 2012-03-27 US disclosed
EP-2205562-B1 1,1,1-TRIFLUORO-2-HYDROXY-3-PHENYLPROPANE DERIVATIVES HOFFMANN LA ROCHE (CH) 2011-03-16 EP disclosed
EP-2205562-A1 1,1,1-TRIFLUORO-2-HYDROXY-3-PHENYLPROPANE DERIVATIVES F. Hoffmann-Roche AG (CH) 2010-07-14 EP disclosed
US-20090088425-A1 GLUCOCORTICOID RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2009-04-02 US disclosed
WO-2009040288-A1 1,1,1-TRIFLUORO-2-HYDROXY-3-PHENYLPROPANE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2009-04-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090088425-A1 GLUCOCORTICOID RECEPTOR ANTAGONISTS NR3C1, NR3C2, MC2R MAOB 1270/4885NPC1 857/4885TDP1 3624/4885
US-20130045972-A1 GLUCOCORTICOID RECEPTOR ANTAGONISTS NR3C1, NR3C2, MC2R MAOB 1270/4885NPC1 857/4885TDP1 3624/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.